Nicast’s first two products, the AVflo vascular access graft and NovaMesh ventral hernia mesh demonstrate the versatility of electrospun nanofabric as a biomaterial from which medical devices with superior properties can be made. The AVflo is intended for patients with end stage renal failure (kidney failure) who must undergo hemodialysis treatment. The NovaMesh is intended to repair ventral (abdominal) hernias. These products address a combined global market of $0.7 billion to $1 billion. Nicast’s future products will focus on additional multi-billion dollar markets in numerous medical fields.
Nicast has long identified the significant potential of electrospinning technology and biomaterials and has been working to apply this technology to a wide range of medical applications.
Additional products in the Nicast pipeline include a nucleus pulposus augmentation hydrogel for herniated discs - implantable via a truly minimally invasive spinal procedure; a smooth cylindrical non-metal stent that can be made drug-eluting and biodegradeable; and advanced drug release devices.
Nicast has six patents in the U.S., nine patents outside of the U.S. and 14 additional patents pending.